CLK2 Drives Platinum Resistance in Ovarian Cancer via BRCA1
2026-04-20
This study uncovers how Cdc2-like kinase 2 (CLK2) promotes platinum resistance in ovarian cancer by phosphorylating BRCA1, thereby enhancing DNA repair. The findings offer mechanistic insight into treatment failure and suggest new targets for overcoming chemotherapy resistance.
GPX4-Dependent GSH Consumption Drives Platinum Resistance in
2026-04-20
This study reveals that glutathione peroxidase 4 (GPX4)-dependent glutathione (GSH) high-consumption underlies acquired platinum chemoresistance in lung cancer brain metastasis. By dissecting the Wnt/NR2F2/GPX4 transcriptional axis, the work identifies new therapeutic directions for overcoming resistance and offers mechanistic insights highly relevant to researchers in cancer and developmental biology.
Redefining Doxycycline: Mechanistic Precision in Translation
2026-04-19
This advanced thought-leadership article explores Doxycycline's evolving role as both a tetracycline antibiotic and a research-grade broad-spectrum metalloproteinase inhibitor, with a focus on its mechanistic impact in cancer and vascular disease models, notably abdominal aortic aneurysm (AAA). Drawing on recent breakthroughs in targeted drug delivery and supported by rigorous evidence, the article delivers actionable guidance for translational researchers, highlights key protocol parameters, and situates APExBIO's Doxycycline (BA1003) as an enabling tool for next-generation studies. The narrative bridges mechanistic rationale, competitive context, and practical strategy, escalating beyond conventional product pages to empower scientific innovation.
ATRX Loss Sensitizes High-Grade Glioma to RTK/PDGFR Inhibiti
2026-04-18
This study demonstrates that high-grade glioma cells lacking ATRX are significantly more susceptible to multi-targeted receptor tyrosine kinase (RTK) and PDGFR inhibitors. The findings highlight the potential for biomarker-driven, combination therapy strategies in gliomas, specifically leveraging ATRX status to optimize antiangiogenic agent use.
L1023 Anti-Cancer Compound Library: Enabling Biomarker-Drive
2026-04-17
The L1023 Anti-Cancer Compound Library delivers a robust platform for high-throughput screening of anti-cancer agents, empowering researchers to interrogate oncogenic pathways with precision. Its compound diversity and streamlined assay-ready format foster rapid target validation and the discovery of pathway-specific inhibitors.
Nigericin Sodium Salt: Precision Tools for Functional Cell A
2026-04-16
Explore how Nigericin sodium salt enables advanced potassium ionophore-based assays for functional cell biology. Discover new insights into optimizing in vitro drug response workflows and cytoplasmic pH regulation.
Coumestrol Induces Ferroptosis in RA-FLS via PMAIP1 Stabiliz
2026-04-15
This study demonstrates that Coumestrol, a phytoestrogen estrogen receptor antagonist, suppresses proliferation and inflammation in rheumatoid arthritis fibroblast-like synoviocytes by inducing ferroptosis through stabilization of mitochondrial PMAIP1. The findings reveal a TRIM3-PMAIP1 pathway as a novel mechanism and highlight Coumestrol’s potential as a lead compound for targeted RA therapies.
Neticonazole Hydrochloride: Dual Antifungal & Cancer Researc
2026-04-14
Neticonazole Hydrochloride stands out as a robust imidazole antifungal with unique applications in both infectious disease and oncology research. Its dual-action—targeting fungal cell membranes and modulating cancer cell exosome pathways—empowers advanced translational workflows for both laboratory and preclinical settings.
Biotin (Vitamin B7, Vitamin H): Data-Driven Lab Solutions
2026-04-13
This article provides scenario-driven guidance for biomedical researchers and lab technicians facing challenges in cell viability, protein labeling, and metabolic assays. Using practical Q&A, we demonstrate how Biotin (Vitamin B7, Vitamin H) (SKU A8010) delivers reproducible, high-purity solutions validated by literature and workflow-tested best practices.
SB 203580 (SKU A8254): Precision p38 MAPK Inhibitor for Reli
2026-04-12
SB 203580 (SKU A8254) offers bench scientists a rigorously validated, highly selective p38 MAPK inhibitor for cell viability, proliferation, and cytotoxicity research. This article provides scenario-driven guidance, practical protocol parameters, and evidence-based troubleshooting to ensure reproducibility and interpretability in MAPK pathway experiments. Discover how APExBIO’s SB 203580 optimizes assay fidelity and workflow efficiency.
AR Heterogeneity in Prostate Cancer: Distinct Therapy Respon
2026-04-12
This study systematically links androgen receptor (AR) expression heterogeneity in prostate cancer to differential responses to castration and enzalutamide therapies. By integrating patient tissue analysis, in vitro functional genomics, and combinatorial therapy experiments, the research identifies BCL-2 as a targetable vulnerability, particularly in AR−/lo castration-resistant prostate cancer.
G-15: A Selective G Protein-Coupled Estrogen Receptor Antago
2026-04-11
G-15 empowers researchers to dissect GPR30-mediated estrogen signaling with unprecedented specificity, enabling robust experimental control over non-classical estrogen pathways. This guide details proven workflows, protocol enhancements, and troubleshooting insights to maximize the utility of G-15 in cellular and in vivo models.
BIBR 1532: Telomerase Inhibitor Workflows for Cancer Researc
2026-04-11
BIBR 1532 stands out as a selective telomerase inhibitor ideal for dissecting cancer cell proliferation pathways and apoptosis mechanisms in both leukemia and solid tumor models. This guide delivers actionable protocols, troubleshooting insights, and comparative data to empower researchers with reproducible, high-impact results.
Probenecid (B2014): MRP Inhibitor and Neuroprotective Age...
2026-04-10
Probenecid, a 4-(dipropylsulfamoyl)benzoic acid derivative, acts as a potent MRP inhibitor and chemosensitizer in multidrug resistance tumor cell models. This article provides a data-driven overview of Probenecid’s mechanisms, benchmarks, and practical limitations for oncology and neuroprotection research.
Mubritinib (TAK 165): Selective Complex I Inhibitor for C...
2026-04-09
Mubritinib (TAK 165) is a potent mitochondrial complex I inhibitor with validated selective cytotoxicity against chemotherapy-resistant AML and KSHV-associated PEL cells. Its clinically relevant activity derives from oxidative phosphorylation inhibition, not HER2 targeting, making it essential for targeted cancer therapy research and apoptosis assays.
466 records 22/32 page Previous Next First page 上5页 2122232425 下5页 Last page